How much revenue does Kexing Biopharm make?

Kexing Biopharm reported 1.41 billion CNY in revenue for fiscal year 2024, up 11.7% from 1.26 billion CNY in fiscal year 2023. In Q2 2025 revenue was 346.91 million CNY.

What companies are similar to Kexing Biopharm?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Teyi Pharmaceutical Group Co.,Ltd (002728.SZ), Shenzhen Weiguang Biological Products Co., Ltd. (002880.SZ), Fuan Pharmaceutical (Group) Co., Ltd. (300194.SZ), Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ).

Kexing Biopharm Co., Ltd. (688136.SS) Stock

About Kexing Biopharm Co., Ltd.

Kexing Biopharm Co., Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of recombinant protein drugs and microecological preparations in China, the European Union, Brazil, the Philippines, and Indonesia. The company focuses on oncology, immunology, and degenerative diseases; and develops new antibodies, proteins, nucleic acid drugs, and antiviral thera...

At a glance

Kexing Biopharm reported revenue of 1.41 billion CNY for fiscal year 2024, up 11.7% from fiscal year 2023, and net income of 31.48 million CNY. In Q2 2025 (the quarter ended June 30, 2025) revenue was 346.91 million CNY, down 13.1% from a year before.

Figures from company filings; latest fiscal year ended December 31, 2024.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.